These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 11723278)

  • 21. Health-related quality of life in patients with relapsing-remitting multiple sclerosis treated with subcutaneous interferon β-1a in Iran.
    Pakdaman H; Amini Harandi A; Gharagozli K; Abbasi M; Tabassi A; Ashrafi F; Ghaffarpor M; Sharifi S; Delavar Kasmae H; Assarzadegan F; Arabahmadi M; Behnam B
    Int J Neurosci; 2017 Jun; 127(6):501-507. PubMed ID: 27279451
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis.
    Kuhle J; Hardmeier M; Disanto G; Gugleta K; Ecsedi M; Lienert C; Amato MP; Baum K; Buttmann M; Bayas A; Brassat D; Brochet B; Confavreux C; Edan G; Färkkilä M; Fredrikson S; Frontoni M; D'Hooghe M; Hutchinson M; De Keyser J; Kieseier BC; Kümpfel T; Rio J; Polman C; Roullet E; Stolz C; Vass K; Wandinger KP; Kappos L;
    Mult Scler; 2016 Apr; 22(4):533-43. PubMed ID: 26362898
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study.
    Bermel RA; Weinstock-Guttman B; Bourdette D; Foulds P; You X; Rudick RA
    Mult Scler; 2010 May; 16(5):588-96. PubMed ID: 20167591
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discordant effect of IFN-beta1a therapy on anti-IFN antibodies and thyroid disease development in patients with multiple sclerosis.
    Monzani F; Meucci G; Caraccio N; Saviozzi M; Casolaro A; Moscato G; Lombardo F; Mosti S; Scagnolari C; Bruschi F; Antonelli G; Ferrannini E; Murri L
    J Interferon Cytokine Res; 2002 Jul; 22(7):773-81. PubMed ID: 12184915
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quality of life during the first 6 months of interferon-beta treatment in patients with MS.
    Arnoldus JH; Killestein J; Pfennings LE; Jelles B; Uitdehaag BM; Polman CH
    Mult Scler; 2000 Oct; 6(5):338-42. PubMed ID: 11064444
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial.
    Chan D; Binks S; Nicholas JM; Frost C; Cardoso MJ; Ourselin S; Wilkie D; Nicholas R; Chataway J
    Lancet Neurol; 2017 Aug; 16(8):591-600. PubMed ID: 28600189
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG).
    Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH
    Mult Scler; 1995 Jun; 1(2):118-35. PubMed ID: 9345462
    [TBL] [Abstract][Full Text] [Related]  

  • 28. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Spinal cord atrophy and disability in multiple sclerosis over four years: application of a reproducible automated technique in monitoring disease progression in a cohort of the interferon beta-1a (Rebif) treatment trial.
    Lin X; Tench CR; Turner B; Blumhardt LD; Constantinescu CS
    J Neurol Neurosurg Psychiatry; 2003 Aug; 74(8):1090-4. PubMed ID: 12876240
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of peginterferon beta-1a and disease factors on quality of life in multiple sclerosis.
    Newsome SD; Guo S; Altincatal A; Proskorovsky I; Kinter E; Phillips G; You X; Sabatella G
    Mult Scler Relat Disord; 2015 Jul; 4(4):350-7. PubMed ID: 26195056
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and tolerability of a 'refrigeration-free' formulation of interferon beta-1b--results of a double-blind, multicentre, comparative study in patients with relapsing-remitting or secondary progressive multiple sclerosis.
    Baum K;
    J Int Med Res; 2006; 34(1):1-12. PubMed ID: 16604818
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH; Alam JJ; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Pullicino PM; Scherokman BJ; Whitham RH
    Ann Neurol; 1996 Mar; 39(3):285-94. PubMed ID: 8602746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors that predict health-related quality of life in patients with relapsing-remitting multiple sclerosis.
    Miller DM; Rudick RA; Baier M; Cutter G; Doughtery DS; Weinstock-Guttman B; Mass MK; Fisher E; Simonian N
    Mult Scler; 2003 Feb; 9(1):1-5. PubMed ID: 12617260
    [TBL] [Abstract][Full Text] [Related]  

  • 34. T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment.
    Barkhof F; van Waesberghe JH; Filippi M; Yousry T; Miller DH; Hahn D; Thompson AJ; Kappos L; Brex P; Pozzilli C; Polman CH;
    Brain; 2001 Jul; 124(Pt 7):1396-402. PubMed ID: 11408334
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiple sclerosis, interferon beta and clinical thyroid dysfunction.
    Kreisler A; de Seze J; Stojkovic T; Delisse B; Combelles M; Vérier A; Hautecoeur P; Vermersch P;
    Acta Neurol Scand; 2003 Feb; 107(2):154-7. PubMed ID: 12580868
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Rudick RA; Goodkin DE; Jacobs LD; Cookfair DL; Herndon RM; Richert JR; Salazar AM; Fischer JS; Granger CV; Simon JH; Alam JJ; Simonian NA; Campion MK; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Whitham RH
    Neurology; 1997 Aug; 49(2):358-63. PubMed ID: 9270562
    [TBL] [Abstract][Full Text] [Related]  

  • 37. No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β1b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study).
    Lanzillo R; Quarantelli M; Pozzilli C; Trojano M; Amato MP; Marrosu MG; Francia A; Florio C; Orefice G; Tedeschi G; Bellantonio P; Annunziata P; Grimaldi LM; Comerci M; Brunetti A; Bonavita V; Alfano B; Marini S; Brescia Morra V;
    Mult Scler; 2016 Aug; 22(9):1163-73. PubMed ID: 26466947
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased disability and MRI lesions after discontinuation of IFN-beta-1a in secondary progressive MS.
    Wu X; Dastidar P; Kuusisto H; Ukkonen M; Huhtala H; Elovaara I
    Acta Neurol Scand; 2005 Oct; 112(4):242-7. PubMed ID: 16146494
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Short communication: treatment of relapsing-remitting multiple sclerosis 96 patients with IFN-beta 1b: results of a 6-year follow-up.
    Bencsik K; Füvesi J; Fricska-Nagy Z; Rajda C; Losonczi E; Török M; Vécsei L
    J Interferon Cytokine Res; 2006 Feb; 26(2):96-100. PubMed ID: 16487029
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interferon β-1b for the treatment of primary progressive multiple sclerosis: five-year clinical trial follow-up.
    Tur C; Montalban X; Tintoré M; Nos C; Río J; Aymerich FX; Brieva L; Téllez N; Perkal H; Comabella M; Galán I; Calle D; Sastre-Garriga J; Rovira A
    Arch Neurol; 2011 Nov; 68(11):1421-7. PubMed ID: 22084124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.